Advertisement

Aging Clinical and Experimental Research

, Volume 28, Issue 3, pp 383–392 | Cite as

“Sundowning” as a biological phenomenon: current understandings and future directions: an update

  • Gowrishankar GnanasekaranEmail author
Review

Abstract

The clinical phenomenon of early evening disruptive behavior also called “Sundowning” in elderly patients has been largely reported in the medical literature without a consistent diagnosis and criteria to define this phenomenon. The current understandings of sundowning are incomplete and current treatment strategies have relied heavily on use of antipsychotic medications, despite side effects and limited evidence to justify their use. A comprehensive understanding of the biogenesis of this phenomenon and mechanistic changes from oxidative pathways may provide novel information on completing the sundowning puzzle. Future studies could examine the utility of natural factors in reviving neuronal energy loss and altering the oxidative pathways might be safe and additional options in development of treatment models for this behavioral disorder.

Keywords

Sundowning Oxidation Sunlight Treatments 

Notes

Compliance with ethical standards

Conflict of interest

Author has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

References

  1. 1.
    Cameron DE (1941) Studies in senile nocturnal delirium. Psychiatr Q 15:47–53CrossRefGoogle Scholar
  2. 2.
    Khachiyants N, Trinkle D, Son SJ et al (2011) Sundown syndrome in persons with dementia: an update. Psychiatry Investig 8:275–287CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bliwise DL, Carroll JS, Lee KA et al (1993) Sleep and “sundowning” in nursing home patients with dementia. Psychiatry Res 48:277–292CrossRefPubMedGoogle Scholar
  4. 4.
    Yesavage JA, Friedman L, Ancoli-Israel S et al (2003) Development of diagnostic criteria for defining sleep disturbance in Alzheimer’s disease. J Geriatr Psychiatry Neurol 16:131–139CrossRefPubMedGoogle Scholar
  5. 5.
    Evans LK (1987) Sundown syndrome in institutionalized elderly. J Am Geriatr Soc 35:101–108CrossRefPubMedGoogle Scholar
  6. 6.
    Gallagher-Thompson D, Brooks JO 3rd, Bliwise D, Leader J, Yesavage JA (1992) The relations among caregiver stress, “sundowning” symptoms, and cognitive decline in Alzheimer’s disease. J Am Geriatr Soc 40:807–810CrossRefPubMedGoogle Scholar
  7. 7.
    Martin J, Marler M, Shochat T et al (2000) Circadian rhythms of agitation in institutionalized patients with Alzheimer’s disease. Chronobiol Int 17:405–418CrossRefPubMedGoogle Scholar
  8. 8.
    Herrmann N, Lanctot KL, Sambrook R et al (2006) The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 21:972–976CrossRefPubMedGoogle Scholar
  9. 9.
    Leslie DL, Inouye SK (2011) The importance of delirium: economic and societal costs. J Am Geriatr Soc 59:S241–S243CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mahoney R, Regan C, Katona C et al (2005) Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study. Am J Geriatr Psychiatry 13:795–801CrossRefPubMedGoogle Scholar
  11. 11.
    Pollak CP, Perlick D (1991) Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 4:204–210CrossRefPubMedGoogle Scholar
  12. 12.
    Cohen-Mansfield J (2007) Temporal patterns of agitation in dementia. Am J Geriatr Psychiatry 15:395–405CrossRefPubMedGoogle Scholar
  13. 13.
    Wu Y-H, Swaab DF (2005) The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 38:145–152CrossRefPubMedGoogle Scholar
  14. 14.
    Vitiello MV, Prinz PN (1989) Alzheimer’s disease. Sleep and sleep/wake patterns. Clin Geriatr Med 5:289–299PubMedGoogle Scholar
  15. 15.
    Bliwise DL (1993) Sleep in normal aging and dementia. Sleep 16:40–81PubMedGoogle Scholar
  16. 16.
    Horiguchi J, Yamashita H, Mizuno S et al (1999) Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol 14:33–36CrossRefPubMedGoogle Scholar
  17. 17.
    Bliwise DL, Hughes M, McMahon PM et al (1995) Observed sleep/wakefulness and severity of dementia in an Alzheimer’s disease special care unit. J Gerontol A Biol Sci Med Sci 50:M303–M306CrossRefPubMedGoogle Scholar
  18. 18.
    Cipriani G, Vedovello M, Nuti A et al (2011) Aggressive behavior in patients with dementia: correlates and management. Geriatr Gerontol Int 11:408–413CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou X, Xu J, Zhao Y (2007) Risk factors of distress in Alzheimer’s patients. Ann Acad Med Singapore 36:253–258PubMedGoogle Scholar
  20. 20.
    Satlin A, Volicer L, Stopa EG et al (1995) Circadian locomotor activity and core-body temperature rhythms in Alzheimer’s disease. Neurobiol Aging 16:765–771Google Scholar
  21. 21.
    Volicer L, Harper DG, Manning BC et al (2001) Sundowning and circadian rhythms in Alzheimer’s disease. Am J Psychiatry 158:704–711CrossRefPubMedGoogle Scholar
  22. 22.
    Steinman MA, Landefeld CS, Rosenthal GE et al (2006) Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 54:1516–1523CrossRefPubMedGoogle Scholar
  23. 23.
    Gallagher P, Barry P, O’Mahony D (2007) Inappropriate prescribing in the elderly. J Clin Pharm Ther 32:113–121CrossRefPubMedGoogle Scholar
  24. 24.
    Berryman SN, Jennings J, Ragsdale S et al (2012) Beers criteria for potentially inappropriate medication use in older adults. Medsurg Nurs 21:129–132 (quiz 133) PubMedGoogle Scholar
  25. 25.
    Blanco-Reina E, Ariza-Zafra G, Ocana-Riola R et al (2012) American geriatrics society beers criteria: enhanced applicability for detecting potentially inappropriate medications in european older adults? A comparison with the screening tool of older person’s potentially inappropriate prescriptions. J Am Geriatr Soc 62:1217–1223CrossRefGoogle Scholar
  26. 26.
    Burkhardt H, Gladisch R (2003) Pharmacotherapy of elderly patients from the clinical viewpoint. Internist (Berl) 44:959–967CrossRefGoogle Scholar
  27. 27.
    Gill SS, Mamdani M, Naglie G et al (2005) A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165:808–813CrossRefPubMedGoogle Scholar
  28. 28.
    Salazar JA, Poon I, Nair M (2007) Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf 6:695–704CrossRefPubMedGoogle Scholar
  29. 29.
    Falsetti AE (2000) Risperidone for control of agitation in dementia patients. Am J Health Syst Pharm 57:862–870PubMedGoogle Scholar
  30. 30.
    McGaffigan S, Bliwise DL (1997) The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs Aging 10:10–17CrossRefPubMedGoogle Scholar
  31. 31.
    Bliwise DL, Watts RL, Watts N et al (1995) Disruptive nocturnal behavior in Parkinson’s disease and Alzheimer’s disease. J Geriatr Psychiatry Neurol 8:107–110CrossRefPubMedGoogle Scholar
  32. 32.
    Fernandez Martinez M, Castro Flores J, Perez de las HZ et al (2008) Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain). Dement Geriatr Cogn Disord 25:103–108CrossRefPubMedGoogle Scholar
  33. 33.
    Fiedorowicz JG, He J, Merikangas KR (2011) The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. J Psychosom Res 70:145–154CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Henderson R, Kurlan R, Kersun JM et al (1992) Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:257–264CrossRefPubMedGoogle Scholar
  35. 35.
    Maes M, Yirmyia R, Noraberg J et al (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24:27–53CrossRefPubMedGoogle Scholar
  36. 36.
    Bachman D, Rabins P (2006) “Sundowning” and other temporally associated agitation states in dementia patients. Annu Rev Med 57:499–511CrossRefPubMedGoogle Scholar
  37. 37.
    Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127CrossRefPubMedGoogle Scholar
  38. 38.
    Bozner P, Grishko V, LeDoux SP et al (1997) The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 56:1356–1362CrossRefPubMedGoogle Scholar
  39. 39.
    Seligman MEP (1972) Learned helplessness. Annu Rev Med 23:407–412CrossRefPubMedGoogle Scholar
  40. 40.
    Willner P, Muscat R, Papp M (1992) Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16:525–534CrossRefPubMedGoogle Scholar
  41. 41.
    Lemaire V, Koehl M, Le Moal M et al (2000) Prenatal stress produces learning deficits associated with an inhibition of neurogenesis in the hippocampus. Proc Natl Acad Sci USA 97:11032–11037CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Luine V, Villegas M, Martinez C et al (1994) Repeated stress causes reversible impairments of spatial memory performance. Brain Res 639:167–170CrossRefPubMedGoogle Scholar
  43. 43.
    Bedrosian TA, Herring KL, Weil ZM et al (2011) Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Proc Natl Acad Sci USA 108:11686–11691CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Sterniczuk R, Dyck RH, Laferla FM et al (2010) Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes. Brain Res 1348:139–148CrossRefPubMedGoogle Scholar
  45. 45.
    Vloeberghs E, Van Dam D, Engelborghs S et al (2004) Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci 20:2757–2766CrossRefPubMedGoogle Scholar
  46. 46.
    Das A, Rai D, Dikshit M et al (2005) Nature of stress: differential effects on brain acetylcholinesterase activity and memory in rats. Life Sci 77:2299–2311CrossRefPubMedGoogle Scholar
  47. 47.
    Friedman L, Brooks JO 3rd, Bliwise DL et al (1995) Perceptions of life stress and chronic insomnia in older adults. Psychol Aging 10:352–357CrossRefPubMedGoogle Scholar
  48. 48.
    Kryger M, Monjan A, Bliwise D et al (2004) Sleep, health, and aging. Bridging the gap between science and clinical practice. Geriatrics 59:24–26, 29–30Google Scholar
  49. 49.
    Allison SP, Lobo DN (2004) Fluid and electrolytes in the elderly. Curr Opin Clin Nutr Metab Care 7:27–33CrossRefPubMedGoogle Scholar
  50. 50.
    Bales CW, Ritchie CS (2002) Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr 22:309–323CrossRefPubMedGoogle Scholar
  51. 51.
    Abbasi AA, Rudman D (1993) Observations on the prevalence of protein-calorie undernutrition in VA nursing homes. J Am Geriatr Soc 41:117–121CrossRefPubMedGoogle Scholar
  52. 52.
    Bozzetti F (2003) Nutritional issues in the care of the elderly patient. Crit Rev Oncol Hematol 48:113–121Google Scholar
  53. 53.
    Chernoff R (2004) Protein and older adults. J Am Coll Nutr 23:627S–630SGoogle Scholar
  54. 54.
    Chidester JC, Spangler AA (1997) Fluid intake in the institutionalized elderly. J Am Diet Assoc 97:23–28 (quiz 29–30) CrossRefPubMedGoogle Scholar
  55. 55.
    Deijen JB, Slump E, Wouters-Wesseling W et al (2003) Nutritional intake and daily functioning of psychogeriatric nursing home residents. J Nutr Health Aging 7:242–246PubMedGoogle Scholar
  56. 56.
    De La Torre JC (2008) Pathophysiology of neuronal energy crisis in Alzheimer’s disease. Neurodegener Dis 5:126–132CrossRefPubMedGoogle Scholar
  57. 57.
    Kuloglu M, Atmaca M, Tezcan E et al (2002) Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive–compulsive disorder. Neuropsychobiology 46:27–32CrossRefPubMedGoogle Scholar
  58. 58.
    Hu X, Weng Z, Chu CT et al (2011) Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci 31:247–261CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Erecinska M, Silver IA (2001) Tissue oxygen tension and brain sensitivity to hypoxia. Respir Physiol 128:263–276CrossRefPubMedGoogle Scholar
  60. 60.
    Gu H, Tang C, Peng K et al (2009) Effects of chronic mild stress on the development of atherosclerosis and expression of toll-like receptor 4 signaling pathway in adolescent apolipoprotein E knockout mice. J Biomed Biotechnol 2009:613879CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Maes M, Kubera M, Obuchowiczwa E et al (2011) Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 32:7–24PubMedGoogle Scholar
  62. 62.
    Campbell S, Marriott M, Nahmias C et al (2004) Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 161:598–607CrossRefPubMedGoogle Scholar
  63. 63.
    Brown ES, Woolston DJ, Frol A et al (2004) Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 55:538–545CrossRefPubMedGoogle Scholar
  64. 64.
    Fournier NM, Duman RS (2011) Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res 227:440–449CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Kim GS, Jung JE, Narasimhan P et al (2012) Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice. Neurobiol Dis 46:440–449CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Maes M, Kubera M, Obuchowiczwa E et al (2011) Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 32:7–24PubMedGoogle Scholar
  67. 67.
    Greve M, O’Connor D (2005) A survey of Australian and New Zealand old age psychiatrists’ preferred medications to treat behavioral and psychological symptoms of dementia (BPSD). Int Psychogeriatr 17:195–205CrossRefPubMedGoogle Scholar
  68. 68.
    Singer C, Tractenberg RE, Kaye J et al (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 26:893–901PubMedPubMedCentralGoogle Scholar
  69. 69.
    Cardinali DP, Furio AM, Brusco LI (2010) Clinical aspects of melatonin intervention in Alzheimer’s disease progression. Curr Neuropharmacol 8:218–227CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    de Jonghe A, Korevaar JC, van Munster BC et al (2010) Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry 25:1201–1208CrossRefPubMedGoogle Scholar
  71. 71.
    Skjerve A, Nygaard HA (2000) Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int J Geriatr Psychiatry 15:1147–1151CrossRefPubMedGoogle Scholar
  72. 72.
    Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57:613–620CrossRefPubMedGoogle Scholar
  73. 73.
    Katz IR, Jeste DV, Mintzer JE et al (1999) Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60:107–115CrossRefPubMedGoogle Scholar
  74. 74.
    Street JS, Clark WS, Kadam DL et al (2001) Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry 16:S62–S70CrossRefPubMedGoogle Scholar
  75. 75.
    Villanyi D, Fok M, Wong RY (2011) Medication reconciliation: identifying medication discrepancies in acutely ill hospitalized older adults. Am J Geriatr Pharmacother 9:339–344CrossRefPubMedGoogle Scholar
  76. 76.
    Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9:364–377CrossRefPubMedGoogle Scholar
  77. 77.
    Huisman-Baron M, van der Veen L, Jansen PA et al (2011) Criteria for drug selection in frail elderly persons. Drugs Aging 28:391–402CrossRefPubMedGoogle Scholar
  78. 78.
    Inouye SK (2000) Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 32:257–263CrossRefPubMedGoogle Scholar
  79. 79.
    Inouye SK, Bogardus ST Jr, Baker DI et al (2000) The hospital elder life program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital elder life program. J Am Geriatr Soc 48:1697–1706CrossRefPubMedGoogle Scholar
  80. 80.
    Fox MT, Sidani S, Persaud M et al (2013) Acute care for elders components of acute geriatric unit care: systematic descriptive review. J Am Geriatr Soc 61:939–946CrossRefPubMedGoogle Scholar
  81. 81.
    Ancoli-Israel S, Martin JL, Gehrman P et al (2003) Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry 11:194–203CrossRefPubMedGoogle Scholar
  82. 82.
    Ancoli-Israel S, Gehrman P, Martin JL et al (2003) Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer’s disease patients. Behav Sleep Med 1:22–36CrossRefPubMedGoogle Scholar
  83. 83.
    Van Someren EJ, Kessler A, Mirmiran M et al (1997) Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 41:955–963CrossRefPubMedGoogle Scholar
  84. 84.
    Fontana Gasio P, Krauchi K, Cajochen C et al (2003) Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly. Exp Gerontol 38:207–216CrossRefPubMedGoogle Scholar
  85. 85.
    Omkar SN, Mour M, Das D (2011) A mathematical model of effects on specific joints during practice of the Sun Salutation–a sequence of yoga postures. J Bodyw Mov Ther 15:201–208CrossRefPubMedGoogle Scholar
  86. 86.
    Lubart R, Lavi R, Friedmann H et al (2006) Photochemistry and photobiology of light absorption by living cells. Photomed Laser Surg 24:179–185CrossRefPubMedGoogle Scholar
  87. 87.
    Rubio CR, Simes JC, Moya M et al (2009) Inflammatory and oxidative stress markers in experimental crystalopathy: their modification by photostimulation. Photomed Laser Surg 27:79–84CrossRefPubMedGoogle Scholar
  88. 88.
    Yu W, Naim JO, McGowan M et al (1997) Photomodulation of oxidative metabolism and electron chain enzymes in rat liver mitochondria. Photochem Photobiol 66:866–871CrossRefPubMedGoogle Scholar
  89. 89.
    Gammack JK, Burke JM (2009) Natural light exposure improves subjective sleep quality in nursing home residents. J Am Med Dir Assoc 10:440–441CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Division of Geriatrics and Palliative Care, Department of Internal MedicineThe University Hospitals Case Medical CenterClevelandUSA

Personalised recommendations